Attorney's Docket No.: 14503-016US1 / F63105PCUS HJW/hor



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wolfram Eichner et al.

Art Unit : 1623

Serial No.: 10/527,554

Examiner: Everett NMN White

Filed

: July 26, 2005

Conf. No.: 7146

Title

: HAS-ALLERGEN CONJUGATE

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL

The following correspondence relating to this application is enclosed for filing:

- 1. Information Disclosure Statement (1 page);
- 2. Form PTO-1449 (15 pages);
- Copies of Cited References (291 references); and 3.
- 4. A Return Postcard.

Please date stamp and return the enclosed postcard. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: Wumber 20, 2006

Elizabeth N. Kaytor, Ph.D.

Reg. No. 53,103

Fish & Richardson P.C. 60 South Sixth Street **Suite 3300** Minneapolis, MN 55402 (612) 335-5070 telephone (612) 288-9696 facsimile

60400873.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit Signature Typed or Printed Name of Person Signing Certificate Attorney's Docket No.: 14503-016US1 / F63105PCUS HJW/hor

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wolfram Eichner et al. Art Unit: 1623

Serial No.: 10/527,554 Examiner: Everett NMN White

Filed : July 26, 2005 Conf. No. : 7146

Title : HAS-ALLERGEN CONJUGATE

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: Neumber 20 2006 Glizheth N. Kayfor

Elizabeth N. Kaytor, Ph.D.

Reg. No. 53,103

Fish & Richardson P.C. 60 South Sixth Street, Suite 3300 Minneapolis, MN 55402 Telephone: (612) 335-5070

Facsimile: (612) 288-9696

60400872.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

December 21, 2006

Date of Deposit

Signature

Lisa M. Becker

Typed or Printed Name of Person Signing Certificate

Substitute Form PTO-1449 (Modelled)

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 14503-016US1

Application No. 10/527,554

Applicant **Information Disclosure Statement**

Wolfram Eichner et al.

by Applicant (Use several sheets if necessary)

Filing Date Group Art Unit March 11, 2005 1623

(37 CFR §1.98(b))

				nt Documents			
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	3,191,291	06/29/65	Maier			
	2	4,064,118	12/20/77	Wong			
	3	4,125,492	11/14/78	Cuatrecasas et al.			
	4	4,179,337	12/18/79	Davis et al.			
	5	4,261,973	04/14/81	Lee et al.			
	6	4,412,989	11/01/83	Iwashita et al.			
	7	4,667,016	05/19/87	Lai et al.			
	8	4,703,008	10/27/87	Lin	·		
	9	4,766,106	08/23/88	Katre et al.			
	10	4,847,325	07/11/89	Shadle et al.			
	11	4,863,964	09/05/89	Hedlund et al.			
	12	4,904,584	02/27/90	Shaw			
	13	5,068,321	11/26/91	Buysch et al.			
	14	5,214,132	05/25/93	Kuga et al.			
	15	5,217,998	06/08/93	Hedlund et al.			
	16	5,218,092	06/08/93	Sasaki et al.			
	17	5,218,108	06/08/93	Sommermeyer et al.			
	18	5,281,698	01/25/94	Nitecki			
	19	5,362,853	11/08/94	Kuga et al.			
	20	5,470,843	11/28/95	Stahl et al.			
	21	5,484,903	01/16/96	Szablikowski et al.	0_0		
	22	5,543,332	08/06/96	Lihme et al.			
	23	5,581,476	12/03/96	Osslund			
	24	5,622,718	04/22/97	Al-Shamkhani et al.			
·	25	6,083,909	07/04/00	Sommermeyer et al.			
	26	6,555,660	04/29/03	Nissen et al.		* .	
	27	2004/0180858	09/16/04	Sommermeyer			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if r	ot in conformance and not considered. Include conv of this form with

next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-016US1	Application No. 10/527,554	
Information Disci		Applicant Wolfram Eichner et al.		
(Use several she		Filing Date March 11, 2005	Group Art Unit 1623	

	Foreig	n Patent Doc	uments or P	ublished Foreign P	atent A	Application	ns	
Examiner	Desig.	Document	Publication	Country or				lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	28	2 441 442	09/26/03	CA				
	29	2 478 478	01/09/04	CA				
	30	2 478 480	01/09/04	CA				
	31	279 486	06/06/90	DD			Abst.	
	32	100 41 541	03/14/02	DE			Abst.	
	33	101 12 825	02/10/02	DE			Abst.	
	34	101 26 158	12/12/02	DE			Abst.	
	35	101 29 369	03/06/03	DE			Abst.	
	36	101 35 694	02/06/03	DE			Abst.	
	37	101 55 098	05/22/03	DE			Abst.	
	38	102 09 821	09/25/03	DE			Abst.	
	39	102 17 994	11/06/03	DE			Abst.	
	40	102 54 745	06/03/04	DE			Abst.	
	41	102 56 558	09/16/04	DE			Abst.	
	42	196 28 705	01/15/98	DE			Abst.	
	43	198 08 079	08/26/99	DE			Abst.	
	44	22 33 977	02/01/73	DE			Abst.	
	45	26 07 706	05/13/93	DE			Abst.	
	46	26 16 086	11/03/77	DE			Abst.	
	47	26 46 854	05/03/89	DE			Abst.	
	48	30 29 307	03/04/82	DE			Abst.	
	49	38 36 600	05/03/90	DE			Abst.	
	50	41 30 807	03/18/93	DE			Abst.	
	51	0 019 403	11/26/80	ЕР				
	52	0 138 572	04/24/85	ЕР				
	53	0 148 605	07/25/90	EP				
	54	0 205 564	05/02/91	EP				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no	at in conformance and not considered. Include copy of this form with

EXAMINER: Initials citation considered. Draw line t next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-016US1	Application No. 10/527,554	
	closure Statement oplicant	Applicant Wolfram Eichner et al.		
(Use several sheets if necessary)		Filing Date March 11, 2005	Group Art Unit 1623	

		n Patent Doo		ublished Foreign F	atent /	Application		
Examiner	Desig.	Document	Publication	Country or	0	Out alasa		lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	55	0 243 929	11/04/87	EP				
	56	0 304 183	02/22/89	EP				
	57	0 307 827	03/22/89	EP				
	58	0 315 349	05/10/89	EP				
	59	0 338 916	10/25/89	EP			Abst.	
	60	0 402 724	06/02/90	EP			Abst.	
-	. 61	0 411 678	01/08/92	EP				
	62	0 418 523	06/21/95	EP				
	63	0 428 267	05/22/91	EP				
	64	0 605 963	07/13/94	EP				
	65	0 609 968	08/10/94	EP				
	66	0 640 619	03/01/95	EP				
	67	0 646 130	04/05/95	EP				
	68	0 668 351	08/23/95	EP				
	69	0 809 996	05/31/96	EP				
	70	1 230 935	08/14/02	EP			Abst.	
	71	1 398 322	09/11/03	EP				
	72	1 398 327	09/11/03	EP				
	73	1 398 328	09/11/03	EP				
,	74	1 400 533	09/11/02	EP				
	75	1 419 080	12/24/75	GB				
-	76	WO 02/80979	10/17/02	WIPO			Abst.	
	77	WO 02/09766	02/07/02	WIPO				
·····	78	WO 02/40057	05/23/02	WIPO				
	79	WO 03/00738	01/03/03	WIPO			Abst.	
	80	WO 03/59246	07/24/03	WIPO				
- · · <u>-</u> · ·	81	WO 03/74087	09/12/03	WIPO			Abst.	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with

next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-016US1	Application No. 10/527,554	
Information Disclo by Appl		Applicant Wolfram Eichner et al.		
(Use several sheets if necessary)		Filing Date	Group Art Unit	
(37 CER &1 08/b))		March 11, 2005	1623	

	Foreig	n Patent Doc		ublished Foreign F	Patent /	Application		
Examiner	Desig.	Document	Publication	Country or	01	0.4.4		lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	82	WO 03/74088	09/12/03	WIPO			Abst.	
	83	WO 04/09082	01/29/04	WIPO				
	84	WO 04/24761	03/25/04	WIPO				
	85	WO 04/50710	06/17/04	WIPO			Abst.	
	86	WO 04/65425	08/05/04	WIPO			Abst.	
	87	WO 90/07939	07/26/90	WIPO				
	88	WO 90/15628	12/27/90	WIPO				
	89	WO 93/23062	11/25/93	WIPO				
	90	WO 94/01483	01/20/94	WIPO				
	91	WO 94/13697	06/23/94	WIPO				
	92	WO 94/28024	12/08/94	WIPO				
	93	WO 94/29370	12/22/94	WIPO				
	94	WO 95/06058	03/02/95	WIPO				
	95	WO 95/13090	05/18/95	WIPO				
	96	WO 96/11953	04/25/96	WIPO				
	97	WO 96/19242	06/27/96	WIPO				
	98	WO 96/40662	12/19/96	WIPO				
	99	WO 96/41813	12/27/96	WIPO				
	100	WO 97/21452	06/19/97	WIPO				
	101	WO 97/30148	08/21/97	WIPO				
	102	WO 97/33552	09/18/97	WIPO				
	103	WO 97/38727	10/23/97	WIPO			Abst.	
	104	WO 98/01158	01/15/98	WIPO		-	Abst.	
	105	WO 98/08856	03/05/98	WIPO			Abst.	
	106	WO 98/20905	05/22/98	WIPO				
	107	WO 98/32466	07/30/98	WIPO			Abst.	
	108	WO 98/56424	12/17/98	WIPO				

Examiner Signature					Date Considered .				

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-016US1	Application No. 10/527,554	
	closure Statement	Applicant Wolfram Eichner et al.		
(Use several sheets if necessary)		Filing Date March 11, 2005	Group Art Unit 1623	

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or	Class	Cubalaaa		lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	109	WO 99/49897	10/07/99	WIPO				

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
	110	Abuchowski and Davis, "Soluble Polymer-Enzyme Adducts," Enzymes as Drugs, 1981, Holcenberg and Rubberts (eds.), Chapter 13, pp. 367-383, John Wiley & Sons N.Y.
	111	Alayash and Cashon, "Hemoglobin and free radicals: implications for the development of a safe blood substitute," Molec. Med. Today, 1995, 1(3):122-127
	112	Ashwell, "Carbohydrate Antigens: Coupling of Carbohydrates to Proteins by a Mixed Anhydride Reaction," Meth. Enzymol., 1972, 28:219-222
	113	Avigad, "A Simple Spectrophotometric Determination of Formaldehyde and Other Aldehydes: Application to Periodate-Oxidized Glycol Systems," <u>Anal. Biochem.</u> , 1983, 134:499-504
	114	Baldwin et al., "Synthesis of Polymer-Bound Hemoglobin Samples," <u>Tetrahedron</u> , 1981, 37:1723-1726
	115	Balland et al., "Intracellular distribution of ampicillin in murine macrophages infected with Salmonella typhimurium and treated with (³ H)ampicillin-loaded nanoparticles," <u>J. Antimicrob.</u> Chemother., 1996, 37:105-115
	116	<u>Anal.</u> , 1994, 12(4):515-522
	117	Bårström et al., "New derivatives of reducing oligosaccharides and their use in enzymatic reactions: efficient synthesis of sialyl Lewis a and sialyl dimeric Lewis x glycoconjugates," <u>Carbohydr. Res.</u> , 2000, 328:525-531
	118	Bauer et al., "Synthesis of w-(Aminooxy)alkanethiols," J. Org. Chem., 1965, 30:949-951
	119	Bauer and Suresh, "S-[w-(Aminoöxy)alkyl]isothiuronium Salts, w,w'-Bis(aminoöxy)alkanes and Related Compounds," J. Org. Chem., 1963, 28:1604-1608
	120	Bendele et al., "Short Communication: Renal Tubular Vacuolation in Animals Treated with Polyethylene-Glycol-Conjugated Proteins," <u>Toxicol. Sci.</u> , 1998, 42:152-157
	121	Benesch, "Bis(pyridoxal) Polyphosphates as Specific Intramolecular Cross-Linking Agents for Hemoglobin," Meth. Enzymol., 1994, 231:267-274
	122	Bepperling et al., "HES 130/0.4, a new HES specification: tissue storage after multiple infusions in rats," Crit. Care, 1999, 3(suppl 1):P153
	123	Berger et al., "Galactosyltransferase-dependent sialylation of complex and endo-N-acetylglucosaminidase H-treated core N-glycans in vitro," FEBS Lett., 1986, 203(1):64-68
	124	Black et al., "N-Bromoacetyl-glycopyranosylamines as affinity labels for a β -glucosidase and a cellulase," Carbohydr. Res., 1993, 250:195-202
	125	Blum et al., "Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels," Electrophoresis, 1987, 8:93-99
	126	Bobbitt, "Periodate Oxidation of Carbohydrates," Carbohydr. Chem., 1956, 11:1-41
	127	Boissel et al., "Erythropoietin Structure-Function Relationships. Mutant proteins that test a model of tertiary structure," J. Biol. Chem., 1993, 268(21):15983-15993

Examiner Signature	Date Considered
	•
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-016US1	Application No. 10/527,554
	losure Statement plicant	Applicant Wolfram Eichner et al.	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date March 11, 2005	Group Art Unit 1623

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
IIIIIai	128	Boturyn et al., "Synthesis of Fluorescent Probes for the Detection of Abasic Sites in DNA," <u>Tetrahedron</u> , 1997, 53(15):5485-5492
	129	Bowen et al., "Estimation of Effective and Total Erythropoiesis in Myelodysplasia Using Serum Transferrin Receptor and Erythropoietin Concentrations, with Automated Reticulocyte Parameters," Leukemia, 1994, 8(1):151-155
	130	Bronzino, The Biomedical Engineering Handbook, CRC Press, USA, Salem, 1995, (TOC only)
	131	Bunn & Jandl, "The Renal Handling of Hemoglobin. II. Catabolism," J. Exp. Med., 1967, 129:925-934
	132	Burgess et al., "Stimulation by Human Placental Conditioned Medium of Hemopoietic Colony Formation by Human Marrow Cells," <u>Blood</u> , 1977, 49(4):573-583
	133	Bystrický et al., "Determination of the cross-linking effect of adipic acid dihydrazide on glycoconjugate preparation," <u>Glycoconj. J.</u> , 1999, 16:691-695
	134	Cabacungan et al., "Amine Boranes as Alternative Reducing Agents for Reductive Alkylation of Proteins," Anal. Biochem., 1982, 124:272-278
	135	Carlsson et al., "Protein Thiolation and Reversible Protein-Protein Conjugation," <u>Biochem J.</u> , 1978, 173:723-737
	136	Cerami, "Beyond Erythropoiesis: Novel Applications for Recombinant Human Erythropoietin," Semin. Hematol., 2001, 38:(3 Suppl 7):33-39
	137	Cerny et al., "A Hydroxyethyl Starch-Hemoglobin Polymer as a Blood Substitute," <u>Clinical Hemorheology</u> , 1982, 2(4):355-365
	138	Chamow et al., "Conjugation of Soluble CD4 without Loss of Biological Activity via a Novel Carbohydrate-directed Cross-linking Reagent," J. Biol. Chem., 1992, 267(22):15916-15922
	139	Chang, "Blood Substitutes Based on Modified Hemoglobin Prepared by Encapsulation or Crosslinking: An Overview," <u>Biomat., Art. Cells & Immob. Biotech.</u> , 1992, 20:159-179
	140	Chagnon et al., "Murine renal cell carcinoma: evaluation of a dendritic-cell tumour vaccine," <u>BJU Int.</u> , 2001, 88:418-424
	141	Chaplin, "Monosaccharides," <u>Carbohydrate analysis: a practical approach</u> , 1996, Chaplin and Kennedy (eds.), Chapter 1, "Oligosaccharides," pp. 37-54
	142	Chaplin, "A Rapid and Sensitive Method for the Analysis of Carbohydrate Components in Glycoproteins Using Gas-Liquid Chromatography," Anal. Biochem., 1982, 123:336-341
	143	Chapman et al., "Therapeutic antibody fragments with prolonged in vivo half-lives," Nature Biotech., 1999, 17:780-783
	144	2001, 86:485-493
	145	Chu et al., "Further Studies on the Immunogenicity of <i>Haemophilus influenzae</i> Type b and Pneumococcal Type 6A Polysaccharide-Protein Conjugates," <u>Infect. Immun.</u> ; 1983, 40:245-256
	146	Cumber et al., "Preparation of Antibody-Toxin Conjugates," Meth. Enzymol., 1985, 112:207-225
	147	Davis and Flitsch, "A Novel Method for the Specific Glycosylation of Proteins," <u>Tetrahed. Lett.</u> , 1991, 32(46):6793-6796
	148	Delgado et al., "The Uses and Properties of PEG-Linked Proteins," Crit. Rev. Ther. Drug Carrier Syst., 1992, 9(3,4):249-304

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-016US1	Application No. 10/527,554
	losure Statement	Applicant Wolfram Eichner et al.	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date March 11, 2005	Group Art Unit 1623

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.				
Initial	ID	Document			
	149	Delorme et al., "Role of Glycosylation on the Secretion and Biological Activity of Erythropoietin," Biochemistry, 1992, 31(41):9871-9876			
	150	Dittmar et al., "Human Glycoproteins and Derived Variants from Recombinant Mammalian Cell Lines," Advances in Protein Design, 1989, 12:145-156			
	151	Dorner et al., "Increased Synthesis of Secreted Proteins Induces Expression of Glucose-regulated Proteins in Butyrate-treated Chinese Hamster Ovary Cells," J. Biol. Chem., 1989, 264(34):20602-20607			
,	152	Dowling and Russell, "Pharmacokinetics of a long-acting oxytetracycline-polyethylene glycol formulation in horses," J. Vet. Pharmacol. Therap., 2000, 23:107-110			
	153	Dreborg and Åkerblom, "Immunotherapy with Monomethoxypolyethylene Glycol Modified Allergens," Crit. Rev. Ther. Drug Carrier Syst., 1990, 6(4):315-365			
	154	Edmunds et al., "Transgenically Produced Human Antithrombin: Structural and Functional Comparison to Human Plasma-Derived Antithrombin," <u>Blood</u> , 1998, 91(12):4561-4571			
-	155	Blum et al., "Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels," Electrophoresis, 1987, 8:93-99			
	156	Elliott et al., "Mapping of the Active Site of Recombinant Human Erythropoietin," <u>Blood</u> , 1997, 89(2): 493-502			
	157	European Pharmacopoeia, "Erythropoietin Concentrated Solution," 3rd Edition, 2000, Monography, pp. 655-660			
	158	European Pharmacopoeia, "Erythropoietin Concentrated Solution," 4th Edition, 2002, Monography, pps. 1123-1128			
	159	Fernández-Santana et al., "Conjugation of 5-azido-3-oxapentyl glycosides with thiolated proteins through the use of thiophilic derivatives," Glycoconj. J., 1998, 15:549-553			
	160	Fibi et al., "Evidence for the Location of the Receptor-Binding Site of Human Erythropoietin at the Carboxyl-Terminal Domain," <u>Blood</u> , 1991, 77(6):1203-1210			
	161	Fibi et al., "N- and O-Glycosylation Muteins of Recombinant Human Erythropoietin Secreted From BHK-21 Cells," <u>Blood</u> , 1995, 85(5):1229-1236			
	162	Fissekis et al., "N-Pantyol-(substituted)amines, Pantothenic Acid Analogues," J. Med. Pharm. Chem., 1960, 2:47-56			
	163	Forno et al., "N- and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line," Eur. J. Biochem., 2004, 271:907-919			
	164	Gaertner and Offord, "Site-Specific Attachment of Functionalized Poly(ethylene glycol) to the Amino Terminus of Proteins," <u>Bioconjugate Chemistry</u> , 1996, 7(1):38-44			
	165	Gervais et al., "NMR investigations of the role of the sugar moiety in glycosylated recombinant human granulocyte-colony-stimulating factor," <u>Eur. J. Biochem.</u> , 1997, 247:386-395			
	166	Gillis et al., "T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for Activity," J. Immunol., 1978, 120(6):2027-2032			
	167	Gonzalez Lio and Thiem, "Chemoenzymatic synthesis of spacer-linked oligosaccharides for the preparation of neoglycoproteins," <u>Carbohydr. Res.</u> , 1999, 317:180-190			
	168	Gould et al., "The Development of Hemoglobin Solutions as Red Cell Substitutes: Hemoglobin Solutions," <u>Transfus. Sci.</u> , 1995, 16:5-17			

Examiner Signature	Date Considered			
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-016US1	Application No. 10/527,554
	losure Statement plicant	Applicant Wolfram Eichner et al.	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date March 11, 2005	Group Art Unit 1623

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
	169	Grabenhorst et al., "Construction of stable BHK-21 cells coexpressing human secretory glycoproteins and human Gal(β1-4)GlcNAc-R α2,6-sialyltransferase: α2,6-Linked NeuAc is preferentially attached to the Gal(β1-4)GlcNAc(β1-2)Man(α1-3)-branch of diantennary oligosaccharides from secreted recombinant β-trace protein," Eur. J. Biochem., 1995, 232:718-725
	170	Grabenhorst and Conradt, "The Cytoplasmic, Transmembrane, and Stem Regions of Glycosyltransferases Specify Their <i>in vivo</i> Functional Sublocalization and Stability in the Golgi," <u>J. Biol. Chem.</u> , 1999, 274(51):36107-36116
	171	Grabenhorst et al., "Biosynthesis and secretion of human interleukin 2 glycoprotein variants from baculovirus-infected Sf21 cells. Characterization of polypeptides and posttranslational modifications," Eur. J. Biochem., 1993, 215:189-197
	172	Grabenhorst et al., "In Vivo Specificity of Human $\alpha 1,3/4$ -Fucosyltransferases III-VII in the Biosynthesis of Lewis" and Sialyl Lewis" Motifs on Complex-type N-Glycans. Coexpression studies from BHK-21 cells together with human β -trace protein," J. Biol. Chem., 1998, 273(47):30985-30994
	173	Grabenhorst et al., "Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells," Glycoconj J., 1999, 16(2):81-97
	174	Gray, "The Direct Coupling of Oligosaccharides to Proteins and Derivatized Gels," <u>Arch. Biochem.</u> <u>Biophys.</u> , 1974, 163:426-428 (Fig. 2.1a)
	175	Greenfield et al., "Evaluation in Vitro of Adriamycin Immunoconjugates Synthesized Using an Acid-sensitive Hydrazone Linker," Cancer Research, 1990, 50:6600-6607
	176	Grimmecke and Brade, "Studies on the reductive amination of 3-deoxy-D-manno-octulosonic acid (Kdo)," Glycoconj. J., 1998, 15:555-562
-	177	Habeeb, "Determination of Free Amino Groups in Proteins by Trinitrobenzenesulfonic Acid," Anal. Biochem., 1966, 14:328-336
	178	Hai et al., "Diaspirin Crosslinked Hemoglobin (DCLHb TM) Polymerization," <u>Art. Cells, Blood Subs.</u> , and Immob. Biotech., 1994, 22(3):923-931
	179	Hallaway et al., "Modulation of Deferoxamine Toxicity and Clearance by Covalent Attachment to Biocompatible Polymers," Proc. Natl. Acad. Sci. USA, 1989, 86:10108-10112
	180	Hamma and Miller et al., "4-(2-Aminooxyethoxy)-2-(ethylureido)quinoline-Oligonucleotide Conjugates: Synthesis, Binding Interactions, and Derivatization with Peptides," <u>Bioconj. Chem.</u> , 2003, 14:320-330
	181	Hartman and Wold, "Cross-Linking of Bovine Pancreative Ribonuclease A with Dimethyl Adipimidate," Biochemistry, 1967, 6(8):2439-2448
	182	Hashimoto et al., "Chemical Modification of the Reducing Chain End in Dextrans and Trimethylsilylation of Its Hydroxyl Groups," <u>J. Polymer Science: Part A: Polymer Chemistry</u> , 1991, 29:1271-1279
	183	Hattori et al., "Reduced Immunogenicity of β-Lactoglobulin by Conjugation with Carboxymethyl Dextran," <u>Bioconjug. Chem.</u> , 2000, 11:84-93
·	184	Herman et al., "Characterization, Formulation, and Stability of Neupogen® (Filgrastim), a Recombinant Human Granulocyte-Colony Stimulating Factor," Formulation, Characterization, and Stability of Protein Drugs, Pearlman and Wang (eds.), Plenum Press, Chapter 7, 1996, pp. 303-328
	185	Hermanson, Bioconjugate Techniques, 1996 (TOC only)

Examiner Signature	Date Considered	
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with	
next communication to applicant.		

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-016US1	Application No. 10/527,554
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wolfram Eichner et al.	
		Filing Date March 11, 2005	Group Art Unit 1623

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	Decument
Initial	ID	Document I Washington for the Marriag of W. Change by High all Aging Eyelenge
	186	Hermentin et al., "A Strategy for the Mapping of N-Glycans by High-pH Anion-Exchange Chromatography with Pulsed Amperometric Detection," Anal. Biochem., 1992, 203(2):281-289
		Higuchi et al., "Role of Sugar Chains in the Expression of the Biological Activity of Human
	187	Erythropoietin," J. Biol. Chem., 1992, 267(11):7703-7709
	188	Sharaf et al., "Studies on Aroyl- and Aryl-Hydrazide Derivatives from D-glycero-D-gulo-Heptono-1,4-Lactone," Carbohydrate Res., 1981, 91:39-48
	189	Inoue et al., "An Improved Method for the Purification of Human Erythropoietin with High in Vivo Activity from the Urine of Anemic Patients," Biol. Pharm. Bull., 1994, 17(2):180-184
	190	Iwamoto et al., "Polysaccharide-Coated Oil Droplets in Oil-in-Water Emulsions as Targetable Carriers for Lipophilic Drugs," J. Pharm. Sci., 1991, 80(3):219-224
	191	Jia et al., "S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control," Nature, 1996, 380:221-226
	192	Jones et al., "A convenient synthesis of <i>N-(tert-</i> butyloxycarbonyl)aminooxy ethers," <u>Tetrahedron Letters</u> , 2000, 41(10):1531-1533
	193	Jones et al., "Multivalent Poly(ethylene glycol)-Containing Conjugates for In Vivo Antibody Suppression," Bioconj. Chem., 2003, 14(6):1067-1076
	194	Kallin, "Coupling of Oligosaccharides to Proteins Using <i>p</i> -Trifluoroacetamidoaniline," Meth. Enzymol., 1994, 242:119-123
	195	Keaney, Jr. et al., "NO Forms an Adduct with Serum Albumin that Has Endothelium-derived Relaxing Factor-like Properties," J. Clin. Invest., 1993, 91:1582-1589
	196	Keipert et al., "Functional properties of a new crosslinked hemoglobin designed for use as a red cell substitute," Transfusion, 1989, 29:768-773
	197	Kitamura et al., "Establishment and Characterization of a Unique Human Cell Line That Proliferates Dependently on GM-CSF, IL-3, or Erythropoietin," J. Cell. Phys., 1989, 140:323-334
	198	Kitamura et al., "Chemical Engineering of the Monoclonal Antibody A7 by Polyethylene Glycol for Targeting Cancer Chemotherapy," Cancer Res., 1991, 51:4310-4315
	199	Kleine-Tebbe et al., "Allergen Immunotherapy – A Position Paper of the German Society for Allergology and Clinical Immunology," Pneumologie, 2001, 55:438-444 (w/English summary)
	200	Klemm et al., "Esterification of Cellulose," Comprehensive Cellulose Chemistry, 1998, Vol. 2, Wiley-VCH, Weinheim, New York, especially chapter 4.4, pps. 99-207
	201	Kobayashi et al., "Reduced Immunogenicity of β-Lactoglobulin by Conjugation with Carboxymethyl Dextra Differing in Molecular Weight," J. Agric. Food Chem., 2001, 49(2):823-831
	202	Kojima et al., "Mitomycin C-dextran conjugate: a novel high molecular weight pro-drug of mitomycin C," J. Pharm. Pharmacol., 1980, 32:30-34
	203	Komatsu et al., "Cloning of granulocyte colony-stimulating factor cDNA from human macrophages and its expression in <i>Escherichia coli</i> ," Jpn. J. Cancer Res., 1987, 78(11):1179-1181
	204	Krantz, "Erythropoietin," Blood, 1991, 77(3):419-434
	205	Krystal, "Physical and Biological Characterization of Erythroblast Enhancing Factor (EEF), a Late Acting Erythropoietic Stimulator in Serum Distinct from Erythropoietin," Exp. Hematol. , 1983, 11(1):18-31
	206	Krystal, "A Simple Microassay for Erythropoietin Based on ³ H-Thymidine Incorporation into Spleen Cells from Phenylhydrazine Treated Mice," <u>Exp. Hematol.</u> , 1983, 11(7):649-660

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-016US1	Application No. 10/527,554
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wolfram Eichner et al.	
		Filing Date March 11, 2005	Group Art Unit 1623

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner	Desig. ID	Document
Initial		Krystal et al., "Purification of Human Erythropoietin to Homogeneity by a Rapid Five-Step
	207	Procedure," <u>Blood</u> , 1986, 67(1):71-79
	208	Kuberan et al., "Preparation and isolation of neoglycoconjugates using biotin-streptavidin complexes," Glycoconj. J., 1999, 16:271-281
	209	Kurtz and Eckardt, "Assays for Erythropoietin," Nephron., 1989, 51(suppl 1):11-14 (w/English summary)
	210	Larionova et al., "Conjugation of the Bowman-Birk Soybean Proteinase Inhibitor with Hydroxyethylstarch," Appl. Biochem. Biotech., 1997, 62:175-182
	211	Lee (ed.), "Synthesis of Peptides and Proteins," Peptide and Protein Drug Delivery, 1991, p. 65
	212	Lee and Lee, "Neoglycoproteins," Glycoproteins II, 1997, Chapter 17, Elsevier Science B.V., pps. 301-620
	213	Leenders et al., "β-Glucuronyl Carbamate Based Pro-moieties Designed for Prodrugs in ADEPT," <u>Tetrahedron Letters</u> , 1995, 36(10):1701-1704
	214	Lees et al., "Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents," Vaccine, 1996, 14(3):190-198
	215	Lesnefsky et al., "High-Dose Iron-Chelator Therapy During Reperfusion with Deferoxamine-Hydroxyethyl Starch Conjugate Fails to Reduce Canine Infarct Size," J. Cardiovasc. Pharmacol., 1990, 16(4):523-528
	216	Levy et al., "Recombinant Antithrombin: Production and Role in Cardiovascular Disorder," <u>Sem.</u> <u>Thromb. Hem.</u> , 2001, 27(4):405-416
	217	Lin et al., "Cloning and expression of the human erythropoietin gene," <u>Proc. Natl. Acad. Sci. USA</u> , 1985, 82:7580-7584
	218	Lindsey at al., "Porphyrin Building Blocks for Modular Construction of Bioorganic Model Systems," Tetrahedron, 1994, 50(30):8941-8968, especially p. 8956
	219	Lomant and Fairbanks, "Chemical Probes of Extended Biological Structures: Synthesis and Properties of the Cleavable Protein Cross-linking Reagent [35]Dithiobis(succinimidyl propionate)," J. Mol. Biol., 1976, 104:243-261
	220	Lönngren and Goldstein, "Coupling of Aldobionic Acids to Proteins Using Water-Soluble Carbodiimide," Meth. Enzymol., 1994, 242:116-118
,	221	Manger et al., "1-N-Glycyl β-Oligosaccharide Derivatives as Stable Intermediates for the Formation of Glycoconjugate Probes," <u>Biochemistry</u> , 1992, 31:10724-10732
	222	Neoglycolipid," Biochemistry, 1992, 31:10733-10740
	223	Maout et al., "Hydroxyethylstarch Conjugated to Human Hemoglobin for use in Blood Transfusion: Comparison with Dextran Conjugates," <u>Carbohydrates and Carbohydrate Polymers - Analysis</u> , <u>Biotechnology, Modification, Antiviral and Other Applications</u> , 1993, Chapter 12, pp. 132-140
	224	McMahon et al., "Pharmacokinetics and Effects of Recombinant Human Erythropoietin After Intravenous and Subcutaneous Injections in Healthy Volunteers," <u>Blood</u> , 1990, 76(9):1718-1722
	225	Meinjohanns et al., "Novel sequential solid-phase synthesis of N-linked glycopeptides from natural sources," J. Chem. Soc., Perkin Trans. 1, 1998, 1:549-560

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
next communication to applicant.	

	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-016US1	Application No. 10/527,554
	Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wolfram Eichner et al.	
			Filing Date March 11, 2005	Group Art Unit 1623

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	226	Mikola and Hänninen, "Introduction of Aliphatic Amino and Hydroxy Groups to Keto Steroids Using O-Substituted Hydroxylamines," <u>Bioconj. Chem.</u> , 1992, 3(2):182-186
	227	Minnema et al., "Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with <i>Escherichia coli</i> ," <u>Blood</u> , 2000, 95(4): 1117-1123
	228	Miyake et al., "Purification of Human Erythropoietin," J. Biol. Chem., 1977, 252(15):5558-5564
	229	Montreuil et al., "Hexuronic acids," <u>Carbohydrate analysis: a practical approach</u> , 1996, Chaplin and Kennedy (eds.), Chapter 5, pp. 175-204
	230	Mosbech et al., "Hyposensitization in asthmatics with mPEG-modified and unmodified house dust mite extract," Allergy, 1990, 45(2):130-141
	231	Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," J. Immunol. Meth., 1983, 65:55-63
	232	Mueller et al., "Recombinant Glycoprotein Product Quality in Proliferation-Controlled BHK-21 Cells," <u>Biotechnol. Bioeng.</u> , 1999, 65(5):529-536
	233	Davis and Flitsch, "A Novel Method for the Specific Glycosylation of Proteins," <u>Tetrahedron Lett.</u> , 1991, 32(46):6793-6796
	234	Nagata et al., "The chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factor," EMBO J., 1986, 5(3):575-581
	235	Nagata et al., "Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor," Nature, 1986, 319:415-418
	236	Nakane et al., "The Accumulation Mechanism of Cationic Mitomycin C-dextran Conjugates in the Liver: In-vivo Cellular Localization and In-vitro Interaction with Hepatocytes," <u>J. Pharm. Pharmacol.</u> , 1988, 40:1-6
	237	Nedospasov and Khomutov, "Synthesis and some properties of aminooxyalkylcelluloses," <u>Bulletin of the Academy of Sciences of the USSR</u> , 1976, Division of Chemical Science, Consultants Bureau, New York, 25:1105-1110
	238	Nimtz et al., "Structural characterization of the oligosaccharide chains of native and crystallized boar seminal plasma spermadhesin PSP-I and PSP-II glycoforms," <u>Eur. J. Biochem.</u> , 1999, 265:703-718
	239	Nimtz et al., "Structures of sialylated oligosaccharides of human erythropoietin expressed in recombinant BHK-21 cells," <u>Eur. J. Biochem.</u> , 1993, 213:39-56
	240	Nimtz et al., "Carbohydrate structures of a human tissue plasminogen activator variant expressed in recombinant Chinese hamster ovary cells," FEBS Lett., 1990, 271:14-18
	241	Nohynek et al., "Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats," Cancer Chemother Pharmacol., 1997, 39:259-266
	242	Nomura et al., "Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoural injection," J. Controlled Release, 1998, 52:239-252
	243	O'Shannessy and Wilchek, "Immobilization of Glycoconjugates by Their Oligosaccharides: Use of Hydrazido-Derivatized Matrices," <u>Analytical Biochemistry</u> , 1990, 191:1
	244	Pawlowski et al., "A new method of non-cross-linking conjugates of polysaccharides to protein via thioether bonds for the preparation of saccharide-protein conjugate vaccines," <u>Vaccine</u> , 1999, 17:1474-1483

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-016US1	Application No. 10/527,554
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wolfram Eichner et al.	
		Filing Date March 11, 2005	Group Art Unit 1623

	Other Do	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
	245	Pazur, "Neutral polysaccharides," <u>Carbohydrate analysis: a practical approach</u> , 1996, Chaplin and Kennedy (eds.), Chapter 3, pp. 55-96
	246	Pedley et al., "The potential for enhanced tumour localization by poly)ethylene glycol) modification of anti-CEA antibody," Br. J. Cancer, 1994, 70:1126-1130
	247	Peeters et al., "Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates," <u>J. Immunol. Meth.</u> , 1989, 120:133-143
	248	Peron et al., "Hydroxyethyl starch-induced renal insufficiency after plasma exchange in a patient with polymyositis and liver cirrhosis," Clin. Nephrol., 2001, 55(5):408-411
	249	Pharma Business, July/August 2000, pages 45-60
	250	Quelle et al., "High-Level Expression and Purification of a Recombinant Human Erythropoietin Produced Using a Baculovirus Vector," <u>Blood</u> , 1989, 74(2):652-657
	251	Rabiner et al., "Evaluation of a stroma-free hemoglobin solution for use as a plasma expander," <u>J. Exp. Med.</u> , 1967, 126:1127-1142
	252	Ragupathi et al., "A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm," Glycoconj. J., 1998, 15:217-221
	253	Ramos et al., "Enzymatic Synthesis of Neoglycopeptide Building Blocks," Angew. Chem. Int. Ed., 2000, 39(2):396-398
	254	Reidhaar-Olson et al., "Identification of Residues Critical to the Activity of Human Granulocyte Colony-Stimulating Factor," <u>Biochemistry</u> , 1996, 35:9034-9041
	255	Relihan et al., "Clearance Rate and Effect on Renal Function of Stroma-Free Hemoglobin Following Renal Ischemia," Ann. Surg., 1972, 176(6):700-704
	256	Richter and de Belder, "Antibodies against Hydroxyethylstarch Produced in Rabbits by Immunization with a Protein-Hydroxyethylstarch Conjugate," Int. Arch. Allergy Appl. Immun.," 1976, 52:307-314
	257	Rogers et al., "Effects of polymerization on the oxygen carrying and redox properties of diaspirin cross-linked hemoglobin," <u>Biochim. Biophys. Acta</u> , 1995, 1248:135-142
	258	Rohrling et al., "Synthesis and testing of a novel fluorescene label for carbonyls in carbohydrates and cellulosics," Synlett, 2001, 5:682-684
,	259	Rose, "Facile Synthesis of Homogeneous Artificial Proteins," J. Am. Chem. Soc., 1994, 116:30-33
	260	Rudolph et al., "Circulation persistence and biodistribution of lyophilized liposome-encapsulated hemoglobin: An oxygen-carrying resuscitative fluid," Crit. Care Med., 1994, 22:142-150
	261	Rudolph, "The Freeze-Dried Preservation of Liposome Encapsulated Hemoglobin: A Potential Blood Substitute," Cryobiology, 1988, 25:277-284
	262	Rush et al., "Microheterogeneity of Erythropoietin Carbohydrate Structure," Anal. Chem., 1995, 67(8):1442-1452
	263	Ruttmann et al., "In vivo investigation into the effects of haemodilution with hydroxyethylstarch (200/0.5) and normal saline on coagulation," Br. J. Anaesthesia, 1998, 80(5):612-616
	264	Sadamoto et al., "Control of Bacteria Adhesion by Cell-Wall Engineering," J. Am. Chem. Soc., 2004, 126:3755-3761

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-016US1	Application No. 10/527,554
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wolfram Eichner et al.	
		Filing Date March 11, 2005	Group Art Unit 1623

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	Decument
Initial	ID	Document
	265	Sadrzadeh et al., "The Long-Acting Parenteral Iron Chelator, Hydroxyethyl Starch-Deferoxamine, Fails to Protect Against Alcohol-Induced Liver Injury in Rats," <u>J. Pharmacol. Exp. Ther.</u> , 1997, 280(2):1038-1042
	266	2000, 11:56-64
	267	Sato et al., "Disposition of a Polymeric Prodrug of Mitomycin C, Mitomycin C-Dextran Conjugate, in the Perfused Rat Liver," J. Pharm. Sci., 1989, 78:11-16
	268	Sawaikar et al., "Products active on mosquitoes. Part VII, Synthesis and biological activity of longifolene derivatives," Indian Journal of Chemistry, 1995, 34B:832-835
	269	Scaglione et al., "A New Model Examining Intracellular and Extracellular Activity of Amoxicillin, Azithromycin, and Clarithromycin in Infected Cells," Chemotherapie, 1993, 39:416-423
	270	Schäfer et al., "Two-year double-blind trial of a monomethoxy polyethylene glycol (mPEG) modified grass pollen extract at different dose levels," Ann. Allergy, 1992, 68(4):334-339
	271	Schlenke et al., "Construction and characterization of stably transfected BHK-21 cells with human- type sialylation characteristic," Cytotechnology, 1999, 30:17-25
	272	Schottelius et al., "Improvement of Pharmacokinetics of Radioiodinated Tyr ³ -Octreotide by Conjugation with Carbohydrates," <u>Bioconjugate Chem.</u> , 2002, 13:1021-1030
	273	Schröter et al., "Male-specific Modification of Human CD52," J. Biol. Chem., 1999, 274(42):29862-29873
	274	Shafer et al., "Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) for use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysaccharides," <u>Vaccine</u> , 2000, 18:1273-1281
	275	Shah et al., "Characterization of Colony-stimulating Activity Produced by Human Monocytes and Phytohemagglutinin-stimulated Lymphocytes," 1977, <u>Blood</u> , 50(5):811-821
	276	Sharef et al "Studies on Aroyl, and Aryl Hydroxide Derivatives from D. glycero D. gylo-Hentono-1 4-
	277	Shirafuji et al., "A new bioassay for human granulocyte colony-stimulating factor (hG-CSF) using murine myeloblastic NFS-60 cells as targets and estimation of its levels in sera from normal healthy persons and patients with infectious and hematological disorders," Exp. Hematol., 1989, 17:116-119
	278	Simmons et al., "Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist," Science, 1997, 276:276-279
	279	Snyder et al., "HbXL99α A hemoglobin derivative that is cross-linked between the α subunits is useful as a blood substitute," <u>Proc. Natl. Acad. Sci. USA</u> , 1987, 84:7280-7284
	280	Shu, "Somogyi Micro Copper Method," Method in Carbohydride Chemistry, 1962, 1:383-388
	281	Song et al., "Toxicity and Antitumor Activity of the Conjugate of Mitomycin C with Carboxymethyl-chitin," Arch. Pract. Pharm., 1993, 53(3):141-147
	282	Souza et al., "Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells," Science, 1986, 232:61-65
	283	Soyez et al., "Biological evaluation of mitomycin C bound to a biodegradable polymeric carrier," <u>J. Controlled Release</u> , 1997, 47:71-80

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no	ot in conformance and not considered. Include copy of this form with
next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-016US1	Application No. 10/527,554
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wolfram Eichner et al.	
		Filing Date March 11, 2005	Group Art Unit 1623

	Other De	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	
Initial	ID	Document
	284	Spivak and Hogans, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 1989, 73:90-99
	285	Staros, "N-Hydroxysulfosuccinimide Active Esters: Bis(N-hydroxysulfosuccinimide) Esters of Two Dicarboxylic Acids Are Hydrophilic, Membrane-Impermeant, Protein Cross-Linkers," Biochemistry, 1982, 21:3950-3955
	286	Sunamoto and Iwamoto, "Protein-Coated and Polysaccharide-Coated Liposomes as Drug Carriers," CRC Critical Review in Therapeutic Drug Carrier Systems, 1986, 2:117-136
	287	Sytkowski et al., "Human erythropoietin dimers with markedly enhanced in vivo activity," Proc. Natl. Acad. Sci. USA, 1998, 95(3):1184-1188
	288	Sytkowski et al., "An Erythropoietin Fusion Protein Comprised of Identical Repeating Domains Exhibits Enhanced Biological Properties," J. Biol. Chem., 1999, 274(35):24773-24778
	289	Takeuchi et al., "Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells," <u>Proc. Natl. Acad. Sci. USA</u> , 1989, 86:7819-7822
	290	Takeuchi and Kobata, "Structures and functional roles of the sugar chains of human erythropoietins," Glycobiology, 1991, 1(4):337-346
	291	Tam et al., "Soluble Dextran-Hemoglobin Complex as a Potential Blood Substitute," Proc. Natl. Acad. Sci. USA, 1976, 73(6):2128-2131
	292	Tanaka et al., "Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats," <u>Cancer Research</u> , 1991, 51:3710-3714
	293	Thomas et al., "Measuring blood volume with fluorescent-labeled hydroxyethyl starch," <u>Crit. Care Med.</u> , 2000, 28(3):627-631
	294	Thomas, "Carbohydrate Binding Sites," Meth. Enzymol., 1977, 46:362-368
	295	Thorpe et al., "Blockade of the galactose-binding sites of ricin by its linkage to antibody," <u>Eur. J. Biochem.</u> , 1984, 140:63-71
	296	Toyama et al., "Surface design of SPR-based immunosensor for the effective binding of antigen or antibody in the evanescent field using mixed polymer matrix," Sensors and Actuators B, 1998, 52:65-71
	297	De Velasco et al., "Synthetic Peptides Representing T-Cell Epitopes Act as Carriers in Pneumococcal Polysaccharide Conjugate Vaccines," <u>Infect. Immun.</u> , 1995, 63(3):961-968
	298	Van Patten et al., "Oxidation of Methionine Residues in Antithrombin," <u>J. Biol. Chem.</u> , 1999, 274(15):10268-10276
	299	Veronese et al., "Surface Modification of Proteins. Activation of Monomethoxy-Polyethylene Glycols by Phenylchloroformates and Modification of Ribonuclease and Superoxide Dismutase," Appl. Biochem. Biotech., 1985, 11:141-152
	300	Vilaseca et al., "Protein conjugates of defined structure: Synthesis and use of a new carrier molecule," <u>Bioconjugate Chemistry</u> , 1993, 4(6):515-520
	301	Webb II and Kaneko, "Synthesis of 1-(Aminooxy)-4-[(3-nitro-2-pyridyl)dithio]butane and 1-(Aminooxy)-4-[(3-nitro-2-pyridyl)dithio]but-2-ene, Novel Heterobifunctional Cross-Linking Reagents," Bioconjugate Chem., 1990, 1:96-99
	302	Weidler et al., "Pharmakokinetische Merkmale als Kriterien für den klinischen Einsatz von Hydroxyethylstärke," <u>ArzneimForsch./Drug Res.</u> , 1991, 41:494-498 (w/English summary)

Examiner Signature	Date Considered			
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with				
next communication to applicant.				

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-016US1	Application No. 10/527,554
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Wolfram Eichner et al.	
		Filing Date March 11, 2005	Group Art Unit 1623

	Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner	Desig.		
Initial	ID	Document	
	303	White and Kennedy, "Oligosaccharides," <u>Carbohydrate analysis: a practical approach</u> , 1996, Chaplin and Kennedy (eds.), Chapter 2, pp. 1-36	
	304	Whitesides et al., "Rates of Thiol-Disulfide Interchange Reactions between Mono- and Dithiols and Ellman's Reagent," J. Org. Chem., 1977, 42(2):332-338	
	305	Wong et al., "Analysis of carbohydrate-protein interactions with synthetic N-linked neoglycoconjugate probes," <u>Biochem. J.</u> , 1993, 296:817-825	
	306	Wong et al., "Synthetic glycosylation of proteins using N -(β -saccharide) iodoacetamides:	
	307	Wong, Chemistry of protein conjugation and cross-linking, 1993, CRCS, Inc. (TOC only)	
	308		
	309	Yalpani et al., "Selective Chemical Modifications of Dextran," J. Polymer Science: Polymer Chemistry Edition, 1985, 23:1395-1405	
	310	Yamaguchi et al., "Effects of site-directed removal of N-glycosylation sites in human erythropoietin on its production and biological properties," J. Biol. Chem., 1991, 266(30):20434-20439	
	311	Yoshida, "Glycamine Formation via Reductive Amination of Oligosaccharides with Benzylamine," Meth. Enzymol., 1994, 247:55-64	
	312	Zalipsky, "Functionalized Poly(ethylene glycol) for Preparation of Biologically Relevant Conjugates," <u>Bioconjugate Chem.</u> , 1995, 6:150-165	
	313	Zara et al., "A Carbohydrate-Directed Heterobifunctional Cross-Linking Reagent for the Synthesis of Immunoconjugates," Anal. Biochem., 1991, 194:156-162	
	314	Zettlmeissl et al., "Characterization of Recombinant Human Antithrombin III Synthesized in Chinese Hamster Ovary Cells," J. Biol. Chem., 1989, 264 (35):21153-21159	
	315	Zhou et al., "Application of capillary electrophoresis, liquid chromatography, electrospray-mass spectrometry and matrix-assisted laserdesorption/ionization - time of flight - mass spectrometry to the characterization of recombinant human erythropoietin," <u>Electrophoresis</u> , 1998, 19(13):2348-2355	
	316	Zou et al., "Allylmalonamide as a bivalent linker: Synthesis of biantennary Gm ₃ -saccharide-Keyhole limpet hemocyanin glycoconjugate and the immune response in mice," <u>Glycoconj. J.</u> , 1999, 16:507-515	
	317	Zucali and Sulkowski, "Purification of human urinary erythropoietin on controlled-pore glass and silicic acid," Exp. Hematol. , 1985, 13(3):833-837	

Examiner Signature	Date Considered	
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		